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Enterovirus D68 – The New Polio?
Hayley Cassidy, Randy Poelman, Marjolein Knoester, Coretta C. Van Leer-Buter and
Hubert G. M. Niesters*
Department of Medical Microbiology and Infection Prevention, Division of Clinical Virology, University of Groningen, University
Medical Center Groningen, Groningen, Netherlands
Enterovirus D68 (EV-D68) has emerged over the recent years, with large outbreaks
worldwide. Increased occurrence has coincided with improved clinical awareness and
surveillance of non-polio enteroviruses. Studies showing its neurotropic nature and the
change in pathogenicity have established EV-D68 as a probable cause of Acute Flaccid
Myelitis (AFM). The EV-D68 storyline shows many similarities with poliovirus a century
ago, stimulating discussion whether EV-D68 could be ascertaining itself as the “new
polio.” Increasing awareness amongst clinicians, incorporating proper diagnostics and
integrating EV-D68 into accessible surveillance systems in a way that promotes data
sharing, will be essential to reveal the burden of disease. This will be a necessary step
in preventing EV-D68 from becoming a threat to public health.
Keywords: Enterovirus D68, emerging, pathogenicity, surveillance, outbreak response
INTRODUCTION
Enterovirus D68: The Virus
Enterovirus D68 is a single-stranded positive-sense RNA virus of the Picornaviridae family,
belonging to the species enterovirus D. EV-D68 was first isolated from respiratory samples in
1962 in California, United States from four pediatric patients presenting with acute respiratory
symptoms. The four isolates obtained from the patients were referred to as the Fermon,
Franklin, Robinson,and Rhyne strains, each presenting with similar antigenic properties. As
a representative strain of the new serotype, the Fermon strain was selected (Imamura and
Oshitani, 2015). Since its first description, EV-D68 has been classified into three genetic
clades, A, B and C. Subclades A1, A2, B1, and B2 have evolved and can be further
identified depending on enterovirus typing, targeting either VP1 or VP4-2 capsid protein
(Nix et al., 2006; Esposito et al., 2015). EV-D68 was also previously known as rhinovirus 87
until it was re-classified in 2002 (Blomqvist et al., 2002). EV-D68 is unusual in that it has
shared characteristics from two key members of the Picornaviridae family; enterovirus and
rhinovirus. Firstly, it has a lower optimal growth temperature of 33◦C (the temperature of the
nose), allowing better replication in the nasal cavity than other EV, and secondly it is acid
Abbreviations: AFM, acute flaccid myelitis; AFP, acute flaccid paralysis; CDC, Centers for Disease Control and Prevention;
CNS, central nerve system; CSF, cerebral spinal fluid; EC50, lower effective concentration; ECDC, European Centre for
Disease Prevention and Control; ENPEN, European Non-Polio Enterovirus Network; ESCV, European Society of Clinical
Virology; EV, enteroviruses; EV-A71, enterovirus A71; EV-D68, enterovirus D68; FDA, Food and Drug Administration; GBS,
Guillain-Barré syndrome; GPEI, Global Polio Eradication Initiative; hIVIG, human intravenous immunoglobulin; ICAM-
5, neuron-expressed intercellular adhesion molecule 5; IP, intraperitoneally; MRI, magnetic resonance imaging; NCIRD,
The National Center for Immunization and Respiratory Diseases; NGS, next generation sequencing; NNDSS, National
Notifiable Diseases Surveillance System; PAHO, Pan American Health Organization; RNA, ribonucleic acid; RT-PCR, reverse
transcriptase PCR; USA, United States; UTR, untranslated region; VP1, viral protein 1; VP4-2, Complete viral protein 4 and
partial viral protein 2; WHO, World Health Organization; WNV, West Nile virus.
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sensitive, meaning it is unable to adequately survive during
passage in the stomach (Foster et al., 2015). Phylogeny however,
shows that EV-D68 is genetically more closely related to EV than
to rhinoviruses. Studies into the cellular receptors of EV-D68
have shown that it targets the α2-6-linked sialic acid, which is
present on cells in the upper respiratory tract, indicating tropism
toward this area (Imamura et al., 2014). This critical difference
in tropism is significant when comparing EV-D68 to poliovirus,
which predominantly reproduces in the gastrointestinal tract. It is
likely that most EV-D68 infections are asymptomatic or present
with a mild respiratory illness however, it is difficult to know
it’s true circulation and burden on the community. Nevertheless,
studies have indicated that circulation of EV-D68 increases over
the summer-autumn season like with other EV (Tokarz et al.,
2012).
The Beginning of Enterovirus
Awareness – The Polio Era
Enteroviruses are thought to have existed and coevolved with
humanity for thousands of years. One of the oldest records
of enterovirus is an Egyptian carving thought to illustrate a
priest with a small, weakened limb, which is considered a
typical feature of a past polio infection. The causative agent of
poliomyelitis (poliovirus), was not discovered until 1908 (Paul,
1971). It was not only the first enterovirus to be discovered, but
also caused the most devastating and widespread morbidity and
mortality of all the enterovirus genotypes. Poliovirus infection
can result in a variety of symptoms, of which AFP that can
cause lifelong disability and may result in death, is the most
typical clinical entity. Awareness of polio increased during the
20th century. This is largely attributed to President Franklin
Roosevelt, himself paralyzed from polio, who was instrumental
in founding the National Foundation for Infantile Paralysis which
started mass worldwide vaccination campaigns (Noor and Krilov,
2016). The first poliovirus vaccine was an inactivated injectable
vaccine, developed by Jonas Salk in 1955. The second vaccine
administered orally, was a vaccine developed by Albert Sabin
in 1961 (Noor and Krilov, 2016). These primary awareness
programs, together with the vaccination campaign, initiated in
the fifties, paved the way for the GPEI created in 1988, which
aimed to eradicate the virus. Over the subsequent years, following
the initial discovery of poliovirus, over 100 enterovirus serotypes
have now been discovered with nearly 70 species infecting
humans (Craighead, 2000). Non-polio EV can cause a variety of
clinical syndromes, ranging from hand-foot and mouth disease to
aseptic meningitis.
sThe introduction of the poliovirus vaccine dramatically
reduced the incidence of infections globally, with only small
clusters sporadically occurring. According to the GPEI, only two
countries, Afghanistan and Pakistan still report endemic wild-
type poliovirus in circulation in 2018 (The Global Poliovirus
Eradication Initiative [GPEI], 2018). Recently, the GPEI also
reported a few new cases of vaccine-derived poliovirus in
the Democratic Republic of the Congo, Nigeria, Somalia and
Papua New Guinea (The Global Poliovirus Eradication Initiative
[GPEI], 2018). Therefore, cases of AFP outside these countries
have decreased to very low numbers. Remaining cases of AFP are
also linked to GBS and neurological infections caused by other
viruses such as WNV and more recently, non-polio EV.
The Rise in Awareness of EV-D68
In the majority of patients, EV-D68 only causes mild
respiratory illness. However, the co-occurrence of EV-D68
and a predominantly severe respiratory disease on one side
and neurological complications of “polio-like” paralysis on the
other side has established EV-D68 as an emerging pathogen
(Holm-Hansen et al., 2016). While EV-D68 has been known
as a respiratory pathogen since its first description in 1962,
the apparent change in pathogenicity into a virus capable of
causing AFP over a relatively short period of time, has led to
increased interest and awareness of the virus in recent years.
This is reflected in the number of published papers. Figure 1
reveals the result of a PubMed search for Enterovirus-D68.
With the disappearance of poliovirus as a major threat to public
health, enterovirus networks such as the ENPEN, have been set
up along with established networks such as the ESCV to focus
on non-polio EV which may become new challenges (Harvala
et al., 2018). EV-D68 has become a compelling topic for research
over the recent years, due to a mix of increased prevalence,
pathology and awareness. This review will explore the EV-D68
story further.
Epidemiology: From Sporadic
Respiratory Virus to Emerging
Neuropathogenic Threat
Enterovirus D68 had only been reported sporadically worldwide
since 2010. Indeed before 2014, only sporadic outbreaks
were reported in the US, the Philippines, Japan and the
Netherlands (Rahamat-Langendoen et al., 2011; Gong et al.,
2016). Significantly, there were only 26 cases reported in the
United States between 1970 and 2005 and only 699 cases
described in Europe, Southeast Asia and Africa between 1970 and
2013 (Holm-Hansen et al., 2016; Wang et al., 2017). However,
it must be noted that specific testing for EV-D68 or routine
FIGURE 1 | The number of published articles on PubMed describing
Enterovirus-D68 from January 2002 to October2018. The number of
published articles for each year is in accordance with EV-D68 interest from the
previous year. ∗Until October.
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typing for EV was and is not standard practice in the majority
of laboratories and assuredly not for testing respiratory samples.
Therefore the true burden of disease is not known and trends
have been likely to be missed. A study published in 2012
reports the analysis of trends in EV-D68 circulation across the
United States and in Africa over two decades (Tokarz et al.,
2012). This was a direct result of increasing sporadic reports
of respiratory disease associated with EV-D68 across North
America, Europe and Asia. The study found the genome had
undergone a rearrangement from the initial Fermon strain in
the spacer region of the 5′UTR, which is known to affect the
translational efficiency and thought to increase the virulence.
Further rearrangement led to a separation into clades A, B and
C, with additional deletions within each clade. Interestingly,
another study (Kaida et al., 2017) reported clade B had specific
substitutions in the BC-loop, which is found on the surface
canyon of the VP1 protein, known to have a role in antigenicity.
This evolution may have had significant implications in the run
up to the 2014 outbreak, but remains unclear so far.
The 2014 Outbreak
In August 2014, the United States and Canada experienced
the first few cases of what resulted in the largest known EV-
D68 outbreak in history. An unprecedented number of cases,
particularly in young children, of severe-respiratory illness was
linked to EV-D68 infections. Unexpectedly, this outbreak of
severe respiratory infections coincided with an upsurge in AFP.
Many of the affected children were also shown to have concurrent
EV-D68 infections. The Polio and Picornavirus Laboratory
Branch of the CDC tested 56 respiratory samples and found
EV-D68 to be the most commonly detected pathogen, with an
overall rate of 20% (11/56) in samples tested. Furthermore the
detection increased to 47% (8/17) in samples collected near onset
of respiratory illness (≤7 days) (Sejvar et al., 2016). Fifty-five
CSF specimens were also tested and found to have one positive
EV-D68 sample (also positive for Epstein-Barr virus) (Sejvar
et al., 2016). The paralysis seen in patients infected with EV-D68
was clinically defined as AFM which was essentially, an acute
onset of AFP with MRI scans showing motor neuron damage
in the myelum. This will be discussed more in detail later in
see section “EV-D68 Case Definition.” In 2014, in the United
States alone, 120 children were reported with AFM which met
the case definition (Messacar et al., 2016). Furthermore, over a
1000 hospital admissions and 12 deaths were associated with an
EV-D68 respiratory infection (Levy et al., 2015). A subsequent
study found that most EV-D68 positive samples associated with
AFM, clustered into the B1 subclade. Interestingly, the study
found that five out of six coding polymorphisms present in
the subclade B1 strains were associated with neuropathogenic
poliovirus (Greninger et al., 2015). These results suggested that
the virus had changed in pathogenicity since the originally
isolated Fermon strain, a hypothesis which was also supported
by results of studies in mice models (Hixon et al., 2017b), which
will be discussed later.
At that time, severe respiratory outbreaks of EV-68 were
reported from several countries across Europe in 2014. During
these outbreaks, cases of AFM were identified, including one
in France and in the United Kingdom and two in Norway
(Lang et al., 2014; Pfeiffer et al., 2015; Varghese et al., 2015;
Holm-Hansen et al., 2016). It is still unclear how frequently
EV-D68 causes AFM compared to the number of respiratory
infections caused by this virus. Estimating this frequency is
currently impossible, firstly as the background circulation of
this relatively emerging virus is unknown and secondly, only
children with severe respiratory illness were tested in the 2014
outbreak in the United States and in Canada, therefore there is
no information on the frequency at which EV-D68 causes mild
symptoms. One study investigated EV-D68 detection by country,
mostly in Northern and Western Europe, during the United
States outbreak (Poelman et al., 2015b). Out of 17,248 respiratory
(majority) specimens tested, 4273 had confirmed picornavirus
detection with 389 samples positive for EV-D68. In Southern
and Eastern Europe, too few samples were tested to draw any
conclusions. Hence, crucial information about how large the
threat of EV-D68 could be, is still missing.
Regarding poliomyelitis, studies have shown that 1 in 200
poliovirus infections led to irreversible paralysis, with 5–10% of
paralysis cases resulting in death due to breathing difficulties
(World Health Organization [WHO], 2018). As AFP is not a
reportable disease in many countries, as long as it is not caused
by poliovirus, it is impossible to say how many potential cases
of EV-D68 associated AFM have occurred during upsurges of
EV-D68 in the past few years. As the link between EV-D68 and
AFM had not been established at that time, many children who
presented with sudden paralysis were not adequately sampled to
detect EV-D68. Subsequent data from the EV-D68 outbreak in
the United States and Canada in 2014 indicates that neurological
complications could occur in 1 out of 100 symptomatic cases
with a total of 1153 confirmed EV-D68 respiratory infections, and
12 EV-D68 positive AFM cases during this period (Sejvar et al.,
2016). Similarly, in Europe, out of 389 confirmed positive samples
in 2014, four AFM cases and one death were associated with
EV-D68 (Poelman et al., 2015b; Varghese et al., 2015). Limited
EV-D68 detection was seen both in the United States and in
Europe in 2015 (Wang et al., 2017).
The 2016 Outbreak
In 2016, a new upsurge in the number of EV-D68 cases was
first reported from the Netherlands. The majority of patients
presented with severe respiratory illness, but one case of AFM
was seen in a 4-year-old boy (Knoester et al., 2017). Phylogenetic
analysis of the samples revealed a different clustering to the
2014 outbreak strains. Simultaneously, similar upsurges were
described by groups in Norway, Denmark, Germany, France,
Spain, Portugal, Sweden, Wales (United Kingdom), Scotland
(United Kingdom) and in the United States (Dyrdak et al., 2016;
ECDC, 2016; Wang et al., 2017). In addition, cases of EV-D68
were also linked with AFM in Wales (2 cases), Scotland (5 cases),
England (1 case), Sweden (3 cases), Italy (2 cases), Spain (3 cases),
France (at least 1) and Argentina (15 cases) with strains clustering
with a divergent B3 lineage (Antona et al., 2016; Dyrdak et al.,
2016, ECDC, 2016; PAHO/WHO, 2016; Williams et al., 2016;
Cabrerizo et al., 2017; Esposito et al., 2017; Giombini et al.,
2017; Kirolos et al., 2017; Stacpoole et al., 2017). A subsequent
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surveillance study (Knoester et al., 2018) presented the results
of a survey which found a total of 29 cases reported of EV-D68
infections associated with AFM in Europe in 2016. Interestingly,
a higher number of EV-D68-associated AFM cases were reported
in Europe in 2016 compared to 2014; 29 versus four cases in
2014. This could suggest the “new” circulating B3 subclade is
more neuropathogenic or perhaps more transmissible than the
B1 clade, which was most frequently reported in 2014. However,
this most likely is due to increased surveillance and awareness
established in 2014. In the United States, 149 AFM cases were
reported in 2016, yet the exact number of AFM cases associated
with EV-D68 is not known. Although there were fewer reported
EV-D68 infections in 2016 in the United States overall, some
AFM cases associated with EV-D68 were reported by Wang et al.,
2017.
Diagnosing an Enterovirus D68 Infection
Sample Collection
Depending on the clinical picture, several diagnostic samples
can and should be collected to detect EV, such as CSF, feces,
respiratory material and serum/plasma (Harvala et al., 2018). As
most EV are transmitted via the fecal-oral route and replicate
in the intestine, high viral loads are usually present in feces,
therefore an effective material for detection and genotyping.
Genotyping or serotyping are necessary and mandatory in cases
of AFP to exclude poliovirus, and stool samples are essential to
achieve this. However, EV-D68 is not readily detected in fecal
samples, in addition it has a rhinovirus-like replication cycle in
the nasal cavity. Indeed, the recently published PAHO/WHO
report now recommends including a respiratory sample if
AFP is suspected (PAHO/WHO report, 2017). Animal models
have shown that EV-D68 can also disseminate to the CNS
by retrograde axonal transport (Morrey et al., 2018). Multiple
material types should therefore be collected if a patient presents
with CNS symptoms: stool, CSF, blood and respiratory samples
(Harvala et al., 2018).
Molecular Testing for Pan-Enterovirus Detection
Molecular testing is recognized as the gold standard for
diagnosing an enterovirus infection. RT-PCR targeting the 5′UTR
region has been established as a routine molecular test in many
laboratories throughout Europe and other parts of the world
(Harvala et al., 2018). It is used as a broad spectrum assay to
detect the presence of EV, without regard to specific subtypes.
The majority of assays are laboratory developed tests and can
be used to screen a panel of suspected pathogens or to detect
a specific target. Rapid and self-contained specimen-to-result
tests such as the FilmArray system (BioFire/bioMerieux, Salt
Lake City, United States) have also been used to screen and
identify enterovirus /rhinovirus simultaneously by combining a
nested multiplex PCR with melting curve analysis (Poritz et al.,
2011). However, further tests would be needed as the Film-
Array cannot distinguish enterovirus from rhinovirus. Additional
FDA approved tests for enterovirus detection are the Cepheid
GeneXpert and SmartCycler (Cepheid, Sunnyvale, California,
United States). Finally, cell cultures can be used, however, they are
not suitable for all enterovirus strains and further identification is
required, using serotyping methods or real-time RT PCR.
A specific RT-PCR was developed to detect EV-D68 during a
European surveillance project in 2014 (Poelman et al., 2015b).
During an EV-D68 season (Summer-Autumn) or during an
upsurge of the virus, a specific RT-PCR could be used for rapid
diagnostics and patient management, and is particularly useful in
the work-up of severe respiratory infections and AFM. During
the 2014 outbreak, a study was carried out where the FilmArray
system was used to detect positive enterovirus samples through
its enterovirus/rhinovirus signals in a respiratory panel (Shibib
et al., 2016). It was consequently found that a positive detection
in the Rhinovirus 1 and 4 targets led to a high association
(13.1× more likely) of EV-D68 found in subsequent samples
sent to the CDC for confirmation. Further point of care tests
were also evaluated during the outbreak. Similarly, the GenMark
eSensor respiratory viral panel (Carlsbad, California, United
States) was found to pick up low-positive rhinoviruses which
were later found to be EV-D68 in 67% of samples, with a 94%
sensitivity and 88% specificity rate (McAllister et al., 2015). This
was subsequently noted due to cross-reactivity with rhinoviruses
(McAllister et al., 2015; Diaz-Decaro et al., 2018).
Molecular Testing for Genotyping
Sanger sequencing of the VP1, and occasionally VP4-2 structural
proteins, following detection of a positive EV sample is
considered the gold standard for the determination of specific
EV genotypes, according to World Health Organization (WHO)
guidelines and Nix et al., 2006. Type specific RT-PCR and
Sanger sequencing techniques have been used increasingly during
outbreaks of EV-A71 in Asia and EV-D68 in the United
States and Europe (Poelman et al., 2015a; Duong et al., 2016).
Sequencing has transformed diagnostics, increasing the amount
of knowledge on pathogens, their circulation and phylogeny.
Phylogenetic analysis can be used more efficiently to look for
genetic relationships within the EV subtype. However, typing
enterovirus remains difficult due to vast variations in the genome
(Midgley et al., 2015).
The development of these molecular tests has also allowed for
the rapid detection and reporting of results in real time. A steady
flow of epidemiological data should be available from health
agencies or regional centers and fed back to the performing labs,
and vice versa. This is not always optimal, and improvements
could be achieved through for example the Antimicrobial,
Infection and Prevention and Diagnostic stewardship model (Dik
et al., 2016).
Next Generation Sequencing
Next generation sequencing, in comparison to the Sanger
targeted approach, allows for the sequencing of multiple reads at
once by reading optical signals after each base addition (Escalona
et al., 2016). Useful information about changes in tropism
or pathogenicity has been obtained by NGS. A retrospective
study into the diversity of EV-D68 during the United States
outbreak in 2014 using NGS technologies (metagenomic shotgun
sequencing) revealed specific polymorphisms C3277A and
A4020G, which triggered functional mutations at cleavage sites
Frontiers in Microbiology | www.frontiersin.org 4 November 2018 | Volume 9 | Article 2677
fmicb-09-02677 November 12, 2018 Time: 16:46 # 5
Cassidy et al. Enterovirus D68 – The New Polio?
2Apro and 3Cpro respectively (Huang et al., 2015). These amino
acid substitutions are suspected to alter protease activity and
increase replication and transmission rates. The group also found
similar mutations in a 2013 strain (US/CO/13-60), thought
to be an ancestor of the 2014 outbreak strains. Indeed these
coding polymorphisms were found to be present in poliovirus,
as mentioned previously (Huang et al., 2015).
EV-D68 ASSOCIATION WITH ACUTE
FLACCID MYELITIS (AFM)
The Strength of EV-D68 Association With
AFM
The upsurge in infection and awareness has led to the expansion
of current scientific knowledge, with several groups now
investigating the depth of the association of EV-D68 with AFM.
Many begin by describing the paralleling of numbers from the
CDC for EV-D68 infections and the cases of AFM for 2014–
2018 (Figure 2; Dyda et al., 2018; Messacar et al., 2018). From
looking at the literature, during and after the United States 2014
outbreak, similar upsurges of severe respiratory and neurological
symptoms were found worldwide, most notably in Northern
Europe. The association was further strengthened by a group
(Aliabadi et al., 2016) which found infection with EV-D68
resulted in a higher odds ratio than two control groups (10×
and 4.5× respectfully) for AFM presentation. Furthermore, the
respiratory prodromal phase prior to paralysis in 65% of patients
(Martin et al., 2016), along with a high involvement of the cranial
and spinal cord, appear to be more specifically associated with
an EV-D68 infection (Messacar et al., 2018). Additionally, AFM
mainly affects children, similarly to EV-D68, which indicates a
specific target population (Dyda et al., 2018).
One of the challenges of the association is that EV-D68 is
not always detected in clinical samples from AFM patients. One
group (Greninger et al., 2015) found EV-D68 in respiratory
samples in approximately 48% of AFM patients (25 cases), where
no other pathogen including EV-D68, could be detected in CSF
samples. Indeed, as discussed previously, detection of EV-D68
in CSF is uncommon. This has only been reported in a handful
of cases (Kreuter et al., 2011; Esposito et al., 2016; Giombini
et al., 2017; Ruggieri et al., 2017). A recent paper (Morrey et al.,
2018) investigated this link through mouse models, deficient in
interferon responses. Mice were challenged IP with EV-D68 of
a known viral load. These researchers detected EV-D68 in the
spinal cord just at early onset of paralysis, compared with the
muscle injection site, which persisted for 6 weeks. The fact that
the virus does not reside in the spinal cord for long could reflect
the challenges in EV-D68 detection in CSF samples. Other viruses
causing neurological disease including poliovirus, EV-A71, WNV
and Rabies are similarly absent from CSF (Huang and Shih,
2015). Awareness of research in this area is particularly important
for clinicians, as once an association is proven, they may be more
inclined to take a respiratory sample and request for EV-D68
testing as well, during suspected AFM cases.
Experiments Revealing the Neurotropic
Nature of EV-D68
The unprecedented upsurge in AFM associated with EV-D68 has
led to many questions into why this emerging virus has become
FIGURE 2 | The number of confirmed United States AFM cases, published on the CDC by month of onset from August 2014-October 2018. The high number of
confirmed AFM cases coincided with the 2014, 2016 and 2018 EV-D68 outbreaks. Figure taken from the NCIRD, AFM in the United States 2018. CDC and NCIRD
(2018) retrieved from https://www.cdc.gov/acute-flaccid-myelitis/afm-surveillance.html.
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so pathogenic, leading to the polio-like paralysis observed. At
present the exact mechanism which EV-D68 uses to instigate
infection remains largely unknown. Studies have shown that
poliovirus can gain access to the CNS through axonal transport
and neuromuscular junctions (Ohka et al., 1998; Huang and
Shih, 2015), and it could be possible that EV-D68 follows a
similar mechanism. A recent study in an EV-D68 mouse model,
links paralysis to infections with EV-D68 through intramuscular
injection by using various strains of the virus, including the
2014 outbreak strains. These injections resulted in the loss
of motor neurons in the anterior horn of the corresponding
spinal cord segments, leading to paralyzed limbs. The study
goes on to suggest that replication of the virus in the motor
neurons causes the damage, paralleling the development of
neurological symptoms (Hixon et al., 2017b). Significantly, the
study fulfills Koch’s postulates by activating paralysis in naïve
mice from EV-D68 isolated from the spinal cord of a paralyzed
mouse.
Much is still unknown about the exact mechanism EV-D68
uses to gain entry and replicate. Recently, a group investigating
the life cycle of EV-D68 has started to answer some of the
questions (Baggen et al., 2018). It was found that EV-D68
binds to synthetic glycoproteins through a terminally linked
sialic acid. This binding induces a conformational change in
the viral capsid, which commences the uncoating process, to
inject the RNA and initiate the replication (Baggen et al.,
2018). Sialic acid has been understood to be a binding
site for other EV, such as Coxsackievirus A24, which was
associated with acute haemorrhagic conjunctivitis (Baggen et al.,
2018).
Wei et al. (2016) identified ICAM-5 as a possible entry
receptor for EV-D68. EV-D68 was believed to bind to the
ICAM-5-Fc receptor, where sialic acid was thought to induce
a conformation change. Crucially, the telencephalon region of
the brain was found to have enhanced ICAM-5 expression,
this receptor could help explain the neurotropism of this virus
(Wei et al., 2016; Messacar et al., 2018). Herpes Simplex Virus-
1, another well-known neurotropic virus, also interacts with
ICAM-5 to mediate cytokine secretion during infection (Tse
et al., 2009). Although these studies shed a light on how EV-
D68 may achieve its neuro-invasive capability, many more
questions remain concerning the factors which determine the
variability in disease severity which is seen in clinical cases.
It is possible that changes in the genome, through mutational
or selection pressure, led to an altered pathogenicity. Evidence
in favor of this hypothesis has been shown by other authors,
describing genogroup replacement between 2006 and 2014
(Xiang et al., 2016), and specific mutations in the puff region
(key neutralization site) of VP2 in EV-D68 strains, which were
isolated from patients with severe respiratory infections. Xiang
et al. (2016) goes on to describe a mutational difference between
the sequences obtained from the United States and China
strains. In the United States strains there was a mutation in
the pseudoknot structure in 3′-UTR, resulting in an altered
phenotype comparatively to the Chinese strains. This could
account for the differences in outbreaks between the United
States and China in 2014.
EV-D68 Case Definition
Although EV-D68 has shown similar neurological presentation to
poliovirus, as well as similar MRI features, it has its own specific
case definition. In response to the increased number of severe
respiratory infections and number of acute paralysis cases during
the 2014 outbreak the CDC proposed the case definition; “onset
of acute limb weakness on or after August 1, 2014, and a magnetic
resonance image (MRI) showing a spinal cord lesion largely
restricted to gray matter in a patient age≤ 21 years” (Washington
State Department of Health, 2016). AFP patients who presented
with pleocytosis (white blood cells >5 mm3) in their CSF who
had a negative or no MRI result were recommended as a probable
case. The terms AFM and AFP are used interchangeably in
articles and reports from 2014. Adding to the confusion is the
restriction of the AFM case definition to individuals younger than
21 years of age, as it is currently understood that AFM does occur
in adults as well. Although mostly children with a chronic illness
were affected, children and adults without any known underlying
condition were also reported (Williams et al., 2016; Stacpoole
et al., 2017). Additionally, it must be updated in accordance with
increased data gained from reports.
The establishment of a case definition for AFM was
particularly important as other diseases such as GBS, may
also present with AFP. Although, paralysis tends to be more
symmetrical in GBS (Jasti et al., 2016). Cases of EV-D68
associated AFM could be diagnosed as “atypical-GBS,” unless an
MRI scan is made or electromyography examinations are carried
out. Typically, EV-D68 associated AFM develops following acute
febrile respiratory syndrome, up to 2 weeks prior to onset of
weakness (Tyler, 2015). Prodromal symptoms compatible with
respiratory infections including shortness of breath (82%), cough
(82%), and rhinorrhoea or nasal congestion (71%) (Martin et al.,
2016) could be incorporated into the case definition.
Clinical Characteristics and Diagnosis of
EV-D68 AFM
Patients presenting with a suspected EV-D68 associated AFM
should undergo a series of examinations to confirm this
diagnosis. One of the most valuable examinations, MRI, was
used extensively during the 2014 outbreak to facilitate the
establishment of a case definition. Patients can present with
a variety of symptoms varying from cough, runny nose and
diarrhea to muscles aches, fever and in some cases respiratory
distress, particularly in children younger than five (National
Center for Immunization and Respiratory Diseases [NCIRD],
Division of Viral Diseases, 2017; Knoester et al., 2018). AFM
symptoms are typically described as asymmetric motor weakness
mostly affecting the upper limbs in the majority of current
known cases. The weakness is flaccid, with deep-tendon reflexes
reduced or absent (CDC and NCIRD, 2015). The cranial nerves
are commonly affected with symptoms such as facial weakness,
dysarthria and dysphagia being described (Tyler, 2015). Most
patients did undergo a spinal tap on presentation, which showed
cerebrospinal fluid pleocytosis in the majority of cases (Tyler,
2015). An MRI scan is essential for the diagnosis, as it shows
lesions in the anterior horn of the gray matter along the spinal
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cord and sometimes in the brainstem (Tyler, 2015). As shown
in the MRI images (Figures 3,4), these distinctive lesions point
at the involvement of the spinal cord motor neurons. It must
be noted that the lesions seen on the MRI scans during cases
of EV-D68 associated AFM are identical to lesions in the spinal
cord which are found in poliomyelitis. Diagnosing a case of AFM
requires input from radiologists, clinical virologists, pediatricians
and neurologists and highlights the need for communication
between specialists to ensure a case is recognized, with the
appropriate samples and tests requested, including PCR and MRI
scans.
Treatment Options
Increasing reports of enhanced pathogenicity and the severity
of the paralysis in the affected individuals have led to urgency
in finding an effective treatment for EV-D68. At present, there
is no vaccine or therapy which exists against EV-D68. A study
carried out by Rhoden et al. (2015) evaluated several anti-viral
candidates for EV-D68, with some promising results; V-7404, a
protease inhibitor currently in development to treat poliovirus
in immunodeficient patients; DAS181, similarly in development
however to treat Influenza and Parainfluenza virus infections,
and finally Rupintrivir, another protease inhibitor, not currently
being developed further. Both V-7404 and Rupintrivir were able
to inhibit all four tested EV-D68 strains (one Fermon and three
2014 outbreak strains). DAS181, which works as a sialidase was
comparable in effectiveness, with a slightly EC50. However, these
results were only obtained from in vitro testing, and clinical
studies with these agents will not be available in the intermediate
future.
FIGURE 3 | MRI of a suspected EV-D68 AFM patient. The MRI presents
sagittal (A,C) and axial images (B,D) of the central nerves system.
(A) Presents a case where the whole central gray matter was involved,
producing a characteristic “H” pattern on axial image (B). (C) Presents a case
where T2 hyperintensity was confined to the left anterior horn cells, which is
demonstrated on the axial image (D). Taken from Maloney et al., 2015. Order
License Id: 4382500446364.
FIGURE 4 | MRI of a poliovirus AFM patient. The MRI presents a sagittal (A)
and an axial image (B) of the central nerves system. (A) presents a case
showing hyperintensities involving the anterior horn cells from C3 to C7.
(B) demonstrates the same case as an axial image. Taken from Haq and
Wasay (2006). Order License Id: 4382500944212.
A further study (Tyler, 2015) investigated the use of an already
FDA approved drug, Fluoxetine, a serotonin inhibitor normally
used as an antidepressant. The study found Fluoxetine inhibited
the replication of EV-D68 in HeLa cells by a direct interaction
with the 2C protein, which is thought to have a function in
assembly. It is unknown if the tested strain was from the 2014
outbreak. However, Fluoxetine administration was noted to result
in low maximal plasma levels, which could lead to problems in
in vivo investigations (Rhoden et al., 2015).
As EV-D68 is a relatively emerging pathogen in terms of
increased pathogenicity in recent years, treatment options are
still far off. Exploring existing treatments for viruses, other
than EV-D68, which present with similar symptoms, is therefore
an attractive strategy (CDC and NCIRD, 2014). Recently,
investigations were carried out (Hixon et al., 2017a) into three
different empiric therapies that could decrease the severity of
paralysis in a mouse model. The mice were intramuscularly
injected with one of the 2014 outbreak strains. Positive results
were obtained with hIVIG, which reduced paralysis and spinal
cord viral loads. Fluoxetine was shown to have a neutral
effect, contrasting to Tyler, 2015 and dexamethasone worsened
outcomes for the mice, causing increased mortality, possibly due
to reducing the immune response and increasing viral replication.
Disadvantageous results of corticosteroid treatment were also
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seen when these agents were used in an outbreak of neuro-
invasive EV-A71 in Cambodia (World Health Organization
[WHO], 2012). So far this research presents promising results
for hIVIG therapy (pre and early post-infection) by providing
potential protection against one of the most severe manifestations
of an EV-D68 infection. Indeed, hIVIG therapy has been
used previously and has arguably been successful in a least
one suspected AFM case associated with WNV (Walid and
Mahmoud, 2009). However, a further study (Chong et al., 2018)
found hIVIG given to patients initially after onset of neurological
symptoms, led to a poor prognosis.
As permanent functional impairment appears to be common
in EV-D68 associated AFM (Messacar et al., 2016), solutions
are also being sought to improve the outcome of patients after
the paralysis has become irreversible. A potentially promising
technique is nerve and muscle transfer, which was historically
used for poliomyelitis associated paralysis (Messacar et al., 2016).
As such, one study (Saltzman et al., 2016) describes the results of a
trial involving nerve transfers in several patients following AFM
associated EV-D68. In most of the cases proximal nerves were
transferred, with one case undergoing bilateral nerve transfers.
The study showed promising results with some muscle strength
regained over a 6-month follow-up.
Non-polio Enterovirus Awareness and Its
Subsequent Increased Surveillance
In the United States, published results from various surveillance
studies are presented through the CDC. However, EV-D68 is only
voluntarily reported in most states in the United States and is not
a national notifiable disease (CDC and NNDSS, 2018). Similarly,
the ECDC does not have an active surveillance system in place
and relies on member states to provide updates on circulation
of various EV. Therefore non-polio enterovirus surveillance in
Europe can also depend on local interests of specific laboratories
and national health institutes. As it is not mandatory to report
EV-D68 in Europe (except Norway), and just in a few states in the
United States, little real-time information is known on the exact
numbers. This is a current challenge for EV-D68 data. However
this may change now that the PAHO/WHO has introduced the
recommendation of including respiratory samples in suspected
EV-D68 cases (PAHO/WHO report, 2017).
Several surveillance systems are in place throughout Europe.
One example is the enhanced non-polio EV surveillance
system implemented in Denmark in which respiratory samples
were included, along with clinical description and genetic
characterisation of the viruses (Barnadas et al., 2017). Similarly,
in collaboration with the Dutch National Institute of Health,
the TYPENED initiative [Typing network Netherlands] is
involved in sequencing and collection of data (Niesters et al.,
2013). In France, two EV National Reference Laboratories
(in Clermont-Ferrand and Lyon) report the number of
enterovirus infections and type of samples analyzed on a regular
basis.1 (Schuffenecker et al., 2016). Additionally, networks such
as ENPEN exist to increase knowledge and communicate both
epidemiological and clinical data during outbreaks, and to chart
1http://cnr.chu-clermontferrand.fr/CNR/
emerging infections. Such networks have been instrumental in
raising awareness of EV-D68 and other non-polio EV through an
email alert system and conferences (Harvala et al., 2018).
DISCUSSION
Burden of Disease and the Problems of
Underdiagnosing
Enterovirus D68 made headlines worldwide in 2014 as a
mysterious, relatively unknown virus was capable of causing
severe illness. The CDC currently monitors and provides
monthly updates on the incidence of AFM, which subsequently
revealed another upsurge in 2016. Since no recent data has
been published on the number of confirmed EV-D68 infections
or the number of AFM cases in Europe, more testing and
communication is required to understand both the EV-D68
infection patterns and the frequency at which this virus causes
AFM. Specific EV-D68 assays have been developed to rapidly
diagnose infections. Despite the existing evidence for the
association between EV-D68 and AFM (Hixon et al., 2017b;
Messacar et al., 2018), EV-D68 is overlooked due to insufficient
knowledge, sampling, laboratory testing and communication
between healthcare professionals and little surveillance from
public health authorities.
Future Perspective and Directions
The current surveillance systems for poliovirus such as GPEI,
environmental and AFP surveillance have been instrumental
in nearly eradicating polio. Integrating EV-D68 into these
established surveillance systems, would be highly effective in
understanding the true burden of disease and prepare hospitals
and laboratories for upcoming outbreaks. NGS has the potential
to be a powerful tool in investigating emerging and untypeable
pathogens. It could also be used to understand the host-pathogen
relationship during an infection and to understand the evolution
of these viruses. However, there are still both technical and
financial obstacles left to overcome before its used in routine
practice (Rutvisuttinunt et al., 2017).
Further outbreaks of EV-D68 can be expected and could
subsequently lead to an increase in EV-D68 associated AFM
cases. EV-D68 numbers and AFM cases have increased in
autumn of 2018. This has been communicated by the EV-D68
network made up of virologists and clinicians who collaborated
during the 2014 and 2016 outbreaks. This has included two
recent AFM cases from the Netherlands. Preliminary typing
results obtained from the University Medical Center Groningen,
the Netherlands, have indicated that recent EV-D68 samples
have clustered into the B3 and A2 subclades. It is imperative
to have effective and streamlined diagnostic procedures along
with stewardship models to deal with the potential increase
in cases. As a result, awareness needs to be created targeting
clinicians and hospital wards in order to make clinical staff are
aware of the virus. Continued interdisciplinary communication
is important to ensure EV-D68 is translated across each medical
field appropriately.
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As effective treatment of EV-D68 infections and AFM are
thus far unsubstantial, the focus may need to be placed on
the development of a vaccine. Currently efficient vaccines are
available for a few members of the enterovirus genus i.e.,
poliovirus and EV-A71 (Klein and Chong, 2015). These viruses
however, have shown high incidences therefore it could be
questioned whether a vaccine should be developed for EV-
D68 at this time for economic reasons. Yet these vaccines have
transformed the fight against these fatal EV. Using current
knowledge and approaches, development of a vaccine against EV-
D68 is technically achievable. A group recently published the
results of a trial involving insect cell-expressed EV-D68 virus-
like particle as a promising candidate for an EV-D68 vaccine
(Dai et al., 2018). At present, the number of infections and life-
threating cases do not reflect those of poliovirus, possibly due to
lack of reporting with the current voluntary reporting systems.
Only increased surveillance and diagnosis will make it possible to
expose the extent of the EV-D68 threat.
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